Meghana Karande, MD

Partner - Head of Life Science & Healthcare

Amplify Resources Group

Braintree, Massachusetts United States

About Me

Physician with incisive knowledge of clinical practice, academia, and industry with robust professional network in the Greater Boston, Greater NYC and SF Bay areas. Breadth and depth of experience in the healthcare industry. An active clinical practitioner for 10+ years with Partner's Health Care and Yale-New Haven Hospital System. Additionally, I have been a consultant to various healthcare entities including digital health start-ups, health insurers, US Govt, Commonwealth of MA and law firms. I am passionate about transforming the healthcare landscape through healthtech innovation. My focus and experience with precise person-centric design thinking (need driven) approach to digital health innovation with strong interest in improving quality of care, outcomes, health and prevention.

You have not backed any projects. Lets change that!
Discover Projects

No project created yet. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No likes on any project yet.. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.